Skip to main content
MANGOCEUTICALS, INC. logo

MANGOCEUTICALS, INC. — Investor Relations & Filings

Ticker · MGRX ISIN · US56270V2051 LEI · 984500BKBD93A8A67E98 US Human health and social work activities
Open in API
Filings indexed 216 across all filing types
Latest filing 2026-05-19 Interim / Quarterly Rep…
Country US United States of America
Listing US MGRX

About MANGOCEUTICALS, INC.

https://www.mangorx.com/

Mangoceuticals, Inc. is a health and wellness company that develops, markets, and sells a variety of products and services through its secure telemedicine platform, MangoRx. The company primarily focuses on men's health, offering treatments for conditions such as erectile dysfunction and providing access to oral testosterone replacement therapy. Mangoceuticals has expanded its portfolio to address the weight management and diabetes markets, offering medications including Semaglutide and Tirzepatide, as well as the patented product Diabetinol for blood sugar and weight control. The company utilizes a direct-to-consumer model to provide convenient and accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-19 English
10-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
Annual Report FY 2025
2026-04-01 English
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
Director's Dealing
2026-03-20 English
4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)
Director's Dealing
2026-03-20 English
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or disclosures by a company. The text specifically mentions "Item 7.01 Regulation FD Disclosure" and includes a press release about new data from field trials related to the company's antiviral compound. There are no detailed financial statements or comprehensive financial analysis present, only a press release attached as an exhibit. The document is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 6332 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the form and content type.
2026-02-23 English
8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about initial sales results of a new product, furnished as an exhibit. There are no detailed financial statements or comprehensive financial analysis present, only a brief disclosure of a press release. The document length is 6151 characters, which is relatively short and consistent with a current report rather than a full financial report. The content does not match categories like Annual Report, Interim Report, Earnings Release, or Management Discussion. It is a regulatory filing announcing a material event, thus best classified as Regulatory Filings (RNS).
2026-02-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.